NEXTCURE INC (NXTC) Stock News

NASDAQ:NXTC - US65343E1082 - Common Stock

5.15 USD

+0.22 (+4.46%)

Last: 9/3/2025, 10:58:51 AM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

NXTC Latest News, Press Relases and Analysis

All

Press Releases

a month ago - By: The Motley Fool

NextCure (NXTC) Q2 Loss Widens 71%

a month ago - By: NextCure

NextCure Provides Business Update and Reports Second Quarter 2025 Financial Results

a month ago - By: NextCure

NextCure Provides Business Update and Reports Second Quarter 2025 Financial Results

a month ago - By: Benzinga - Mentions: IVA PIII TTNP HCTI ...

12 Health Care Stocks Moving In Friday's Intraday Session

a month ago - By: Benzinga - Mentions: CNC ZYXI XTLB SRPT ...

12 Health Care Stocks Moving In Friday's Pre-Market Session

a month ago - By: NextCure

Preclinical Data Demonstrate Anti-Siglec-15 Treatment Improves Bone Microarchitecture and Reduces Fracture Incidence in Mice with Moderate-to-Severe Osteogenesis Imperfecta

a month ago - By: NextCure

Preclinical Data Demonstrate Anti-Siglec-15 Treatment Improves Bone Microarchitecture and Reduces Fracture Incidence in Mice with Moderate-to-Severe Osteogenesis Imperfecta

3 months ago - By: NextCure

NextCure and Simcere Zaiming Announce Strategic Partnership for a Novel Antibody-Drug Conjugate Targeting CDH6

3 months ago - By: NextCure

NextCure and Simcere Zaiming Announce Strategic Partnership for a Novel Antibody-Drug Conjugate Targeting CDH6

3 months ago - By: NextCure

NextCure and LigaChemBio to Present Trial in Progress Poster for LNCB74, a B7-H4 Targeted Antibody-Drug Conjugate, as Monotherapy in Participants with Advanced Solid Tumors at ASCO 2025

3 months ago - By: NextCure

NextCure and LigaChemBio to Present Trial in Progress Poster for LNCB74, a B7-H4 Targeted Antibody-Drug Conjugate, as Monotherapy in Participants with Advanced Solid Tumors at ASCO 2025

3 months ago - By: Yahoo Finance - Mentions: GAP TAL GOOS GOOG ...

The Gap, Inc. (GAP) Is A “Star,” Says Jim Cramer

3 months ago - By: Yahoo Finance - Mentions: GOOS TAL AXP NVDA ...

Canada Goose Holdings Inc. (GOOS) Has Been “Terrific,” Says Jim Cramer

4 months ago - By: NextCure

NextCure Provides Business Update and Reports First Quarter 2025 Financial Results

4 months ago - By: NextCure

NextCure Provides Business Update and Reports First Quarter 2025 Financial Results

5 months ago - By: NextCure

NextCure to Present at 24th Annual Needham Virtual Healthcare Conference

5 months ago - By: NextCure

NextCure to Present at 24th Annual Needham Virtual Healthcare Conference

6 months ago - By: NextCure

NextCure Provides Business Update and Reports Full Year 2024 Financial Results

6 months ago - By: NextCure

NextCure Provides Business Update and Reports Full Year 2024 Financial Results

8 months ago - By: NextCure

NextCure Announces First Patient Dosed in the Phase 1 Study of LNCB74 (B7-H4 ADC) as Therapeutic for Treating Multiple Cancers

8 months ago - By: NextCure

NextCure Announces First Patient Dosed in the Phase 1 Study of LNCB74 (B7-H4 ADC) as Therapeutic for Treating Multiple Cancers

9 months ago - By: NextCure

NextCure Announces Acceptance of IND Application for LNCB74

9 months ago - By: NextCure

NextCure Announces Acceptance of IND Application for LNCB74

9 months ago - By: NextCure

NextCure to Participate in the 36th Annual Piper Sandler Healthcare Conference

9 months ago - By: NextCure

NextCure to Participate in the 36th Annual Piper Sandler Healthcare Conference

10 months ago - By: NextCure

Preclinical Data Demonstrates Anti-Siglec-15 Treatment Enhanced Generation of Quality Bone with Better Mechanical Properties in Mice with Moderate-to-Severe Osteogenesis Imperfecta